Virax Biolabs Group Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Cash & Equivalents	6.44	4.23	3.59	9.35	0.02
Cash & Short-Term Investments	6.44	4.23	3.59	9.35	0.02
Cash Growth	52.26%	17.82%	-61.62%	42888.32%	23.47%
Other Receivables	0.03	0.03	0.22	-	-
Total Trade Receivables	0.03	0.03	0.22	-	-
Inventory	-	0.09	0.06	-	0.02
Other Current Assets	0.36	0.54	0.51	0.28	0.01
Total Current Assets	6.83	4.89	4.38	9.63	0.05
Net Property, Plant & Equipment	1.5	1.53	1.1	-	-
Other Intangible Assets	-	-	-	0.18	-
Total Assets	8.32	6.43	5.48	9.81	0.05
Accounts Payable	0.58	0.59	0.12	0.72	1.24
Short-Term Debt	0.03	0.03	-	0.15	-
Current Portion of Leases	0.08	0.05	0.05	-	-
Unearned Revenue	-	-	-	0.04	-
Other Current Liabilities	-	-	-	-	0
Total Current Liabilities	0.69	0.67	0.17	0.91	1.25
Long-Term Leases	0.3	0.29	0.18	-	-
Total Long-Term Liabilities	0.3	0.29	0.18	-	-
Total Liabilities	0.99	0.96	0.35	0.91	1.25
Common Stock	0.01	0	0	0	0
Additional Paid-in Capital	37.49	30.17	23.89	20.92	5.36
Accumulated Other Comprehensive Income	-0.31	0.11	0	-0	-0
Retained Earnings	-29.61	-24.59	-18.53	-11.79	-6.34
Total Common Shareholders' Equity	7.58	5.7	5.37	9.13	-0.97
Minority Interest	-0.24	-0.23	-0.23	-0.22	-0.22
Shareholders' Equity	7.33	5.46	5.14	8.9	-1.2
Total Liabilities & Equity	8.32	6.43	5.48	9.81	0.05
Total Debt	0.41	0.38	0.22	0.15	0
Net Cash (Debt)	6.02	3.85	3.36	9.21	0.02
Net Cash Growth	56.40%	14.47%	-63.45%	42216.10%	23.47%
Net Cash Per Share	15.15	25.82	41.93	216.52	0.57
Book Value	7.58	5.7	5.37	9.13	-0.97
Book Value Per Share	19.06	38.17	66.87	214.64	-25.48
Tangible Book Value	7.58	5.7	5.37	8.95	-0.97
Tangible Book Value Per Share	19.06	38.17	66.87	210.45	-25.48

SEC Filings: 10-K · 10-Q